WAY-100635 is a potent dopamine D4 receptor agonist
暂无分享,去创建一个
Bryan L. Roth | David E. Nichols | Val J. Watts | B. Roth | B. Armbruster | V. Watts | Blaine N. Armbruster | Benjamin R. Chemel | Blaine Armbruster | D. Nichols | B. Chemel
[1] K. Neve,et al. Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors , 1999, Psychopharmacology.
[2] Allan Fletcher,et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.
[3] R. Carnahan,et al. Aripiprazole, a Novel Atypical Antipsychotic Drug , 2004, Pharmacotherapy.
[4] Jan Passchier,et al. Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system , 2001, European Journal of Nuclear Medicine.
[5] K. Neve,et al. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. , 1996, Molecular pharmacology.
[6] R. Mailman,et al. Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.
[7] D. Jackson,et al. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299. , 1997, The Journal of pharmacology and experimental therapeutics.
[8] C. Dourish,et al. Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. , 1993, Trends in pharmacological sciences.
[9] I. Cliffe,et al. A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT(1A) receptor PET radioligands. , 2000, Nuclear medicine and biology.
[10] P A Sargent,et al. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.
[11] P. Grasby,et al. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. , 1996, Nuclear medicine and biology.
[12] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[13] D. Donnelly-roberts,et al. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist , 2005, Neuropharmacology.
[14] P. Salmi,et al. In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors 1 Presented in part at the `9th ECNP Congress', Amsterdam, September 21–25, 1996 (Ahlenius et al., 1996). 1 , 1999, European Neuropsychopharmacology.
[15] Paul Ernsberger,et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[16] H. Kung,et al. Synthesis and evaluation of 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p- iodobenzamido]ethyl]piperazine (p-MPPI): a new iodinated 5-HT1A ligand. , 1994, Journal of medicinal chemistry.
[17] I A Cliffe,et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.
[18] A Malizia,et al. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. , 1995, European journal of pharmacology.
[19] J. Passchier,et al. Visualisation of serotonin-1 A ( 5-HT 1 A ) receptors in the central nervous system , 2022 .
[20] Bryan L. Roth,et al. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.